Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance

References

• Zhao X, Jiang R, Zu Y, et al. Process optimization studies of 10-Hydroxycamptothecin (HCPT)-loaded folate-conjugated chitosan nanoparticles by SAS-ionic crosslink combination using response surface methodology (RSM). Appl Surf Sci 2012;258:2000–5
   Web of Science ®Google Scholar
• Hu W, Zhang C, Fang Y, Lou C. Anticancer properties of 10-hydroxycamptothecin in a murine melanoma pulmonary metastasis model in vitro and in vivo. Toxicol In Vitro 2011;25:513–20
   PubMed Web of Science ®Google Scholar
• Carbonero R, Supko J. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641–61
   PubMed Web of Science ®Google Scholar
• O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34:1500–8
   PubMed Web of Science ®Google Scholar
• Jaxel C, Kohn KW, Wani MC, et al. Structure–activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res 1989;49:1465–9
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang M, Wang Q, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J Control Release 2007;119:153–62
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Guarino AM, Call JB, et al. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Cancer Chemother Rep 1970;54:461–70
   PubMedGoogle Scholar
• Tiwari AK, Sodani K, Wang S-R, et al. Nilotinib (AMN107, Tasigna®) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153–61
   PubMed Web of Science ®Google Scholar
• Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco 2002;57:385–415
   PubMedGoogle Scholar
• Müller RH, Maassen S, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release 1997;47:261–9
   Web of Science ®Google Scholar
• Müller RH. Lipid nanoparticles: recent advances. Adv Drug Deliv Rev 2007;59:375–6
   Web of Science ®Google Scholar
• Priyanka K, Abdul Hasan SA. Preparation and evaluation of Montelukast sodium loaded solid lipid nanoparticles. J Young Pharm 2012;4:129–37
   PubMedGoogle Scholar
• Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997;24:337–44
   Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491–504
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, et al. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013;171:349–57
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004;277:39–61
   PubMed Web of Science ®Google Scholar
• Podduturi VP, Magaña IB, O’Neal DP, Derosa PA. Simulation of transport and extravasation of nanoparticles in tumors which exhibit enhanced permeability and retention effect. Comput Methods Prog Biomed 2013;112:58–68
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65:71–9
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189–207
   PubMedGoogle Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Kim B-D, Na K, Choi H-K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 2005;24:199–205
   PubMed Web of Science ®Google Scholar
• Miao J, Du Y-Z, Yuan H, et al. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloid Surf B 2013;110:74–80
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Wientjes MG, Au JLS. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012;64:29–39
   PubMed Web of Science ®Google Scholar
• Li S-D, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. BBA Biomembranes 2009;1788:2259–66
   PubMed Web of Science ®Google Scholar
• Seo S-J, Akaike T, Choi Y-J, et al. Alginate microcapsules prepared with xyloglucan as a synthetic extracellular matrix for hepatocyte attachment. Biomaterials 2005;26:3607–15
   PubMed Web of Science ®Google Scholar
• Cho CS, Seo SJ, Park IK, et al. Galactose-carrying polymers as extracellular matrices for liver tissue engineering. Biomaterials 2006;27:576–85
   PubMed Web of Science ®Google Scholar
• Chen D, Guo P, Chen S, et al. Properties of xyloglucan hydrogel as the biomedical sustained-release carriers. J Mater Sci Mater Med 2012;23:955–62
   PubMed Web of Science ®Google Scholar